NEONATAL MEDICATION PROTOCOLS

RANITIDINE
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	**RANITIDINE**
PRESENTATION:	Ampoule: 50mg/5mL Mixture: 15mg/mL
ACTION & INDICATION:	Histamine (H_2) receptor antagonist, which competitively inhibits the action of histamine thereby decreasing gastric acid secretion. For: (i) short term treatment of gastric and duodenal ulcers (ii) treatment of pathologic GI hypersecretory conditions e.g. Short Gut syndrome (iii) short term symptomatic relief of gastro-oesophageal reflux.
DOSE :	**Use solution prepared in Pharmacy if available.** IV: 0.5 mg/kg/dose every 12 hours Oral: 2 mg/kg/dose every 8 hours
PREPARATION:	IV: Take 5mL and dilute it to 20mL with sodium chloride 0.9% = 2.5mg/mL May be further diluted if required Compatible with sodium chloride and glucose solutions.
ADMINISTRATION:	Oral: May be given at any time with regard to feeds. IV: Administer over at least five minutes
ADVERSE EFFECTS & COMMENTS:	Tachycardia Bradycardia Diarrhoea, constipation Rash Vomiting Abdominal pain Raised ALT (alanine aminotransferase)
REFERENCES:	Neofax 2013
DATE:	October 2013